Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study

Antzeko izenburuak

• Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study
  nork: Sheppard, Michael, et al.
  Argitaratua: (2014)
• Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study
  nork: Bronstein, Marcello D., et al.
  Argitaratua: (2016)
• Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
  nork: Colao, A., et al.
  Argitaratua: (2014)
• Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
  nork: Chiloiro, Sabrina, et al.
  Argitaratua: (2021)
• Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study
  nork: Colao, Annamaria, et al.
  Argitaratua: (2020)